Media coverage about Rockwell Medical (NASDAQ:RMTI) has trended positive on Thursday, according to Alpha One Sentiment Analysis. The research firm, a service of Accern, scores the sentiment of news coverage by analyzing more than twenty million blog and news sources. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Rockwell Medical earned a news sentiment score of 0.44 on Alpha One’s scale. Alpha One also gave news headlines about the company an impact score of 50 out of 100, meaning that recent news coverage is somewhat likely to have an impact on the company’s share price in the near future.
These are some of the headlines that may have effected AlphaOne’s scoring:
- BRIEF-Rockwell Medical says Richmond, Ravich each personally own less than 1 pct of co (feeds.reuters.com)
- Glass Lewis Supports Election of Mark H. Ravich to Rockwell Medical, Inc. Board (finance.yahoo.com)
- Rockwell Medical Issues Letter To Shareholders Explaining Why Electing Could Do Lasting Harm (biospace.com)
- ETFs with exposure to Rockwell Medical, Inc. : May 22, 2017 (finance.yahoo.com)
- ISS Supports Election of Mark H. Ravich to Rockwell Medical, Inc. Board (finance.yahoo.com)
Separately, Zacks Investment Research raised shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, March 28th.
Rockwell Medical (NASDAQ:RMTI) traded up 2.82% during mid-day trading on Thursday, reaching $7.30. 99,156 shares of the company were exchanged. The stock’s 50-day moving average price is $7.24 and its 200-day moving average price is $6.43. The stock’s market capitalization is $380.02 million. Rockwell Medical has a 1-year low of $3.55 and a 1-year high of $10.58.
Rockwell Medical (NASDAQ:RMTI) last announced its earnings results on Tuesday, May 9th. The company reported ($0.09) EPS for the quarter, meeting analysts’ consensus estimates of ($0.09). Rockwell Medical had a negative return on equity of 33.60% and a negative net margin of 37.98%. The company had revenue of $14.60 million during the quarter, compared to analysts’ expectations of $12.66 million. During the same period last year, the business posted ($0.10) EPS. Rockwell Medical’s revenue for the quarter was up 7.4% on a year-over-year basis. On average, equities research analysts anticipate that Rockwell Medical will post ($0.39) EPS for the current fiscal year.
In other news, insider David S. Richmond bought 37,210 shares of the stock in a transaction that occurred on Wednesday, March 22nd. The stock was bought at an average cost of $5.84 per share, for a total transaction of $217,306.40. Following the acquisition, the insider now directly owns 176,412 shares of the company’s stock, valued at approximately $1,030,246.08. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kenneth L. Holt sold 6,000 shares of the firm’s stock in a transaction dated Thursday, March 16th. The shares were sold at an average price of $5.98, for a total value of $35,880.00. Following the transaction, the director now owns 17,430 shares of the company’s stock, valued at $104,231.40. The disclosure for this sale can be found here. Company insiders own 15.90% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Mideast Time and is the sole property of of Mideast Time. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.mideasttime.com/favorable-press-coverage-somewhat-likely-to-impact-rockwell-medical-rmti-stock-price/1724367.html.
About Rockwell Medical
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Ratings for Rockwell Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.